Is CytomX Therapeutics, Inc. (CTMX) a Buy, Sell, or Hold?
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$3.66 USD
-$0.04 (-1.08%)
- Volume
- 4.61M
- Average Volume
- 4.32M
- Market Capitalization
- $588.61M
- P/E Ratio
- -10.13
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $8.21
- Year Low
- $1.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $10.38
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Sean A. McCarthy |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CTMX |
| CUSIP | 23284F105 |
| CIK | 0001501989 |
| Web | https://www.cytomx.com |
| Phone | 650 515 3185 |
| Currency | USD |
| Employees | 69 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 10.38 |
| Quick Ratio | 10.38 |
| Cash Ratio | 0.85 |
Sales & Book Value
| Annual Sales | $76.2M |
| Price / Sales | 16.56 |
| Cash Flow | -0.45 |
| Price / Cash Flow | -7.34 |
| Price / Book | 2.03 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $16.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | -63.40% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 21 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.15 |
| Trailing P/E Ratio | -10.13 |
| PEG Ratio | 0.06 |
| P/E Growth | 0.06 |
| Net Income | $-17.37M |
| Net Margin | -166.40% |
| Pretax Margin | -165.74% |
| Return on Equity | -36.61% |
| Return on Assets | -16.46% |
Financials Score
| AltmanZ Score | 6.84 |
| Piotroski Score | 1.00 |
| Working Capital | 319.07M |
| Total Assets | 359.36M |
| Ebit | -58.91M |
| Market Cap | 595.05M |
| Total Liabilities | 39.41M |
Poll Results
About CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progre ... ssing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
2026-07-08 13:01:06
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2026-06-10 11:22:12
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-03 08:00:00
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY ® and Regeneron's Veloci-Bi ® platforms -
CytomX Therapeutics: Cashed Up With Catalysts Ahead
2026-05-26 11:32:18
In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, extending its cash runway and enabling broader Varseta-M development. CTMX's cash position of $346.7M supports operations into at least H2'28, with anticipated increased R&D spending as programs expand.
CytomX Therapeutics to Present at Upcoming June Investor Conferences
2026-05-21 08:00:00
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in June.
2026-05-18 08:00:00
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Mamata Gokhale, Ph.D.
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
2026-05-07 22:51:19
CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript
CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 20:11:22
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.27 per share a year ago.
Frequently Asked Questions
-
What is the current CytomX Therapeutics, Inc. (CTMX) stock price?
-
CytomX Therapeutics, Inc.(NASDAQ:CTMX) stock price is $3.66 in the last trading session. During the trading session, CTMX stock reached the peak price of $8.21 while $1.72 was the lowest point it dropped to. The percentage change in CTMX stock occurred in the recent session was --1.08% while the dollar amount for the price change in CTMX stock was -$-0.04.
-
CTMX's industry and sector of operation?
-
The NASDAQ listed CTMX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CTMX?
-
Marcia Belvin | Senior Vice President & Chief Scientific Officer
Stephanie Robertson | Senior Vice President of Alliances & Program Leadership
Lloyd A. Rowland Jr. | Senior Vice President, General Counsel, Chief Compliance Officer & Secretary
Yu-Waye Chu | Senior VP & Chief Medical Officer
Danielle Olander-Moghadassian | Senior Vice President & Chief Human Resources Officer -
How many employees does CTMX have?
-
Number of CTMX employees currently stands at 69. CTMX operates from 151 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
Link for CTMX official website?
-
Official Website of CTMX is: https://www.cytomx.com
-
How do I contact CTMX?
-
CTMX could be contacted at phone #650 515 3185 and can also be accessed through its website. CTMX operates from 151 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
How many shares of CTMX are traded daily?
-
The average number of CTMX shares traded daily for last 3 months was 4.32M.
-
What is the market cap of CTMX currently?
-
The market value of CTMX currently stands at $588.61M with its latest stock price at $3.66